Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347687 | 0.77 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL2111019 | 0.77 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL4384511 | 0.77 | LOXL2 (0.63) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL28886053 | 0.77 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL15662691 | 0.77 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL28812467 | 0.76 | LOXL2 (0.53) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL4280580 | 0.75 | LOXL2 (0.56) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL1160528 | 0.74 | LOXL2 (0.55) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL2986028 | 0.74 | LOXL2 (0.55) | LOXL2HRH3AHR | |
| SCHEMBL3022232 | 0.74 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093408-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-09-23 | — | — | CN | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-4028130-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | Shionogi & Co., Ltd (JP) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| CN-114401965-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| EP-3976031-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | Shionogi & Co., Ltd (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3330256-B1 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-11008320-B2 | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2021-05-18 | — | — | US | disclosed |
| WO-2021050708-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | SHIONOGI & CO., LTD. (JP) | 2021-03-18 | — | — | WO | disclosed |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| EP-2832731-A1 | AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772480-A1 | HIV REPLICATION INHIBITOR | Shionogi & Co., Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2752410-A1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014065434-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-05-01 | — | — | WO | disclosed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | LOXL2 1938/4885MTNR1A 2727/4885MTNR1B 2634/4885 |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | LOXL2 2032/4885MTNR1A 197/4885MTNR1B 76/4885 |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | CYC1, MT-CO1, ABCB11 | LOXL2 4816/4885MTNR1A 1154/4885MTNR1B 1117/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | LOXL2 3884/4885MTNR1A 3021/4885MTNR1B 3168/4885 |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | LOXL2 1843/4885MTNR1A 750/4885MTNR1B 402/4885 |
| US-11008320-B2 | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | NTRK2, NTRK3, NTRK1 | LOXL2 3803/4885MTNR1A 117/4885MTNR1B 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.